rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

vTv Therapeutics Inc.

VTVT · Nasdaq

Health CareBiotechnologyNot moving yet

VTVT stood above a rising 150-day average in 32 of the last 52 weekly readings, and has been out of that trend for the last 16 weeks. It is 18.3% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−9 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 16
Industry in uptrend
18% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
42 (+8)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 32 of 52 weeks.

23 Apr – 22 Oct
18%29%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$81KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders42+8 on the quarter
New · exited16 · 7
Reported value$60.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
SAMSARA BIOCAPITAL, LLCunchanged · filed 14 Aug 2026298,496$11.2M00.0%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 2026269,874$10.2M+63,586+30.8%
FMR LLCunchanged · filed 13 Aug 2026260,391$9.8M00.0%
Siren, L.L.C.unchanged · filed 13 Aug 2026163,000$6.1M00.0%
BAKER BROS. ADVISORS LPunchanged · filed 14 Aug 2026148,314$5.6M00.0%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 202694,463$3.6M-14,459−13.3%
Trails Edge Capital Partners, LPreduced · filed 14 Aug 202685,192$3.2M-54,386−39.0%
Aisling Capital Management LPnew · filed 13 Aug 202650,000$1.9M+50,000
MARSHALL WACE, LLPadded · filed 13 Aug 202639,560$1.5M+26,171+195.5%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202632,470$1.2M-416−1.3%
30 Sep 2023 – 30 Jun 2026
22241Sep 23Jun 24Mar 25Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Anne M. Phillips Company insiderDirector · last 26 Jun 20260 · 0
BAKER BROS. ADVISORS LP Company insiderDirector · last 26 Jun 20260 · 0
Daniel K. Spiegelman Company insiderDirector · last 26 Jun 20260 · 0
Fahed Al-Marzooqi Company insiderDirector · last 26 Jun 20260 · 0
Julian Baker Company insiderDirector · last 26 Jun 20260 · 0
Srinivas Akkaraju Company insiderDirector · last 26 Jun 20260 · 0
Michael Stephen Tung Company insiderEVP & CFO · last 17 Feb 20260 · 0
Paul J. Sekhri Company insiderPres, CEO and Exec Chairperson · last 17 Feb 20262 · 0
Felix Baker Company insiderDirector · last 10 Jun 20250 · 0
667, L.p. Company insiderDirector · last 25 Jun 20240 · 0
Samsara Biocapital, L.p. Company insider10% owner · last 5 Mar 20240 · 0
Steven L. Tuch Company insiderChief Financial Officer · last 27 Feb 20240 · 0

Same industry

MRNA ModernaLeading+118%
ENTX Entera BioLeading+51%
XNCR XencorLeading+44%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-39.4%
Cash and equivalentsFY 2025 · to 31 Dec 2025$88.9M
Free cash flowFY 2024 · to 31 Dec 2024−$25.3M

Analyst forecasts

No analyst forecasts yet.